Organic Pressurized Fluid Patents (Class 424/45)
  • Patent number: 10279046
    Abstract: The present invention relates to a composition for treating an ocular inflammatory disease, comprising hydrophilic sulfasalazine and hyaluronic acid, and a preparation method therefor. Furthermore, the present invention relates to a method for treating an ocular inflammatory disease, which comprises administering, to an individual, a therapeutically effective amount of hydrophilic sulfasalazine and hyaluronic acid.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: May 7, 2019
    Assignee: CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Choun-Ki Joo, Jun-Sub Choi
  • Patent number: 10258569
    Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: April 16, 2019
    Assignee: MEXICHEM AMANCO HOLDINGS S.A. DE C.V.
    Inventors: Stuart Corr, Timothy James Noakes
  • Patent number: 10258568
    Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 16, 2019
    Assignee: MEXICHEM AMANCO HOLDINGS S.A. DE C.V.
    Inventors: Stuart Corr, Timothy James Noakes
  • Patent number: 10258547
    Abstract: The present invention relates to a cosmetic composition in the foam form comprising, in a physiologically acceptable medium, at least one aqueous phase, talc and one UV sunscreen ingredient. It also relates to a cosmetic composition in the foam form comprising, in a physiologically acceptable medium, at least one aqueous phase, at least 1% by weight of at least one mineral filler relative to its total weight, and one UV sunscreen ingredient.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: April 16, 2019
    Assignee: L'OREAL
    Inventor: Takehiko Kasai
  • Patent number: 10251900
    Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: April 9, 2019
    Assignee: INSMED INCORPORATED
    Inventors: Gina Eagle, Renu Gupta
  • Patent number: 10238697
    Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: March 26, 2019
    Assignee: ARES TRADING S.A.
    Inventors: Philippe Langella, Jean-Marc Chatel, Luis Bermudez-Humaran, Camille Aubry, Laurence Goffin, Simone Favre-Zimmerli, Yolande Chvatchko
  • Patent number: 10226483
    Abstract: The present invention generally relates to topical compositions and methods of using the same. The topical compositions may comprise a hydrophilic composition and a hydrophobic composition in admixture. The hydrophobic composition may include a nitric oxide-releasing compound such as, for example, a diazeniumdiolate functionalized co-condensed silica particle. In some embodiments, the topical composition may be self-emulsifying. Further described herein are kits comprising a hydrophilic composition and a hydrophobic composition.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: March 12, 2019
    Assignee: Novan, Inc.
    Inventors: Ryan Doxey, Jian Bao
  • Patent number: 10201672
    Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: February 12, 2019
    Assignee: MannKind Corporation
    Inventors: Chad C. Smutney, P. Spencer Kinsey, Carl R. Sahi, Benoit Adamo, John M. Polidoro, Scott McLean, Dennis Overfiled, Anthony Bryant
  • Patent number: 10195139
    Abstract: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: February 5, 2019
    Assignee: Shin Nippon Biomedical Laboratories, Ltd.
    Inventors: Ryoichi Nagata, Shunji Haruta
  • Patent number: 10179139
    Abstract: Described herein is a pharmaceutical composition that includes a beta2-agonist selected from indacaterol and formoterol in combination with a corticosteroid selected from fluticasone and ciclesonide, and, optionally, one or more pharmaceutically acceptable excipients.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: January 15, 2019
    Assignee: CIPLA Limited
    Inventors: Geena Malhotra, Shrinivas Madhukar Purandare
  • Patent number: 10179145
    Abstract: A hemostatic tissue sealant sponge and a spray for acute wounds are disclosed. The sponge comprises hydrophobically modified polymers that anchor themselves within the membrane of cells in the vicinity of the wound. The seal is strong enough to substantially prevent the loss of blood inside the boundaries of the sponge, yet weak enough to substantially prevent damage to newly formed tissue upon recovery and subsequent removal of the sponge. In examples, the polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The spray comprises hydrophobically modified polymers that form solid gel networks with blood cells to create a physical clotting mechanism to prevent loss of blood. In an example, the spray further comprises at least one reagent that increases the mechanical integrity of the clot. In another example, the reagent prevents microbial infection of the wound.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: January 15, 2019
    Assignees: University of Maryland, College Park, University of Maryland, Baltimore
    Inventors: Matthew Dowling, John Hess, Grant Bochicchio, Srinivasa Raghavan
  • Patent number: 10166268
    Abstract: The present disclosure provides methods for treating obstructive sleep apnea (OSA) and OSA induced cardiorespiratory diseases. The disclosure provides, inter alia, methods for treating or alleviating: OSA or OSA induced hypertension, cardiac arrhythmias, myocardial ischemia, sudden cardiac death or stroke, by administering oxytocin. The disclosure further provides methods for improving sleep satisfaction in OSA patients by administering oxytocin.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: January 1, 2019
    Assignee: THE GEORGE WASHINGTON UNIVERSITY
    Inventors: David Mendelowitz, Vivek Jain, Heather Jameson, Jay Shawn Kimbro
  • Patent number: 10166247
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: January 1, 2019
    Assignee: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • Patent number: 10159769
    Abstract: Methods of making medical devices are described. A method of making a medical device for delivering a bioactive includes preparing a suitable solution comprising the bioactive; placing a vessel containing the solution over a substrate comprising a biocompatible foam and defining open cells; initiating flow of the solution from the vessel and toward the substrate such that the solution exits the vessel and contacts the substrate; and maintaining flow of the solution for an amount of time sufficient to achieve a desired volume of the solution within the substrate. Medical devices made by the methods are also described.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: December 25, 2018
    Assignee: Cook Medical Technologies LLC
    Inventor: Colleen Gemborys
  • Patent number: 10139321
    Abstract: The present disclosure relates to a mucolytic tablet for a sample collection device that causes mucolysis of biological samples collected in the sample collection device. The mucolytic tablet includes N-acetyl L-cysteine (NALC), a pharmaceutically active mucolytic agent that reduces the viscosity of mucus containing biological samples. The mucolytic tablet also includes one or more chelating agents, water-soluble anti-adherent/s, and at least one buffering agent.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: November 27, 2018
    Assignee: Alpha-Tec Systems, Inc.
    Inventors: Richard Williams, Anne Frontella, Mark Williams
  • Patent number: 10130573
    Abstract: The present invention is a composition and method of treatment for skin disorders, conditions, and severe skin dryness in general through topical systematic and periodic application of a formulation that generally may include salicylic acid, glycolic acid, urea, dimethyl isosorbide, ethoxydiglycol, barrier repair agents, anti-irritants, humectants, and also has an acidic pH formulation.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: November 20, 2018
    Assignee: Clark Pharmaceuticals LLC
    Inventors: Stephen W. Clark, Natalie Barger
  • Patent number: 10092588
    Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: October 9, 2018
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Enbal Ziv, Yohan Hazot, David Schuz
  • Patent number: 10045940
    Abstract: This invention relates to compositions (e.g., otic compositions) comprising an antibiotic (generally a quinolone or naphthyridinone), corticosteroid, and organic acid (generally a fatty acid). This invention also relates to treatment methods using such a composition, uses of such a composition to make medicaments, and therapeutic kits comprising such a composition.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: August 14, 2018
    Assignee: Intervet Inc.
    Inventors: Keith A. Freehauf, Jay Brumfield, Roger Tully
  • Patent number: 10039799
    Abstract: A non-invasive topical cream comprising 500 mg garlic, 1 tbs castor oil, 2 tbs virgin coconut oil, 2 tbs African shea butter, 1 tbs Pau D?Arco, and 1 tbs bacitracin for treating and managing breast health.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: August 7, 2018
    Inventor: Lillian Jenkins
  • Patent number: 10034866
    Abstract: This invention relates to a solution formulation comprising a tiotropium salt, 12-20% ethanol, 0.1-1.5% of water, 0.05-0.10% citric acid (or other organic acid) and an HFA propellant, wherein the percentages are percentages by weight based on the total weight of the formulation. The invention also provides a p MDI comprising a canister containing the formulation.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: July 31, 2018
    Assignee: TEVA Branded Pharmaceutical Products R&D, Inc.
    Inventor: Xian-Ming Zeng
  • Patent number: 10023623
    Abstract: The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: July 17, 2018
    Assignee: Alkermes, Inc.
    Inventors: Juan Alvarez, Jean Chamoun, Heather C. Losey
  • Patent number: 10006091
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: June 26, 2018
    Assignees: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca I Estudis Avançats
    Inventors: Roger Gomis, Evarist Planet
  • Patent number: 10004764
    Abstract: Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (RBC MPs), which are depleted of hemoglobin (Hb) and express phosphatidylserine on their surface, for the treatment of lung disease. Administration of RBC MPs to the lung via inhalation promotes the production of immunoregulatory cytokines (such as IL-10), and reduces inflammation and injury in the lung.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: June 26, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Janet S. Lee, Timothy E. Corcoran, Valerian Kagan
  • Patent number: 9987337
    Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: June 5, 2018
    Assignee: PROTHERA, INC.
    Inventor: Stephen Francis Olmstead
  • Patent number: 9987375
    Abstract: Anionic liposomes and apolipoprotein B-100 targeted immunoliposomes as therapeutic agents for dyslipidemia and related diseases, and compositions and methods for preparing same.
    Type: Grant
    Filed: September 21, 2014
    Date of Patent: June 5, 2018
    Inventors: Amirhossein Sahebkar, Ali Badiee, Mahmoud Reza Jaafari
  • Patent number: 9981030
    Abstract: Described herein are synthetic glycan conjugates comprising a carrier and a glycan moiety derived from Neisseria meningitidis, wherein the glycan moiety is covalently linked to the carrier through a linker. Also provided herein are a mixture of the glycan conjugates thereof, immmunogenic compositions thereof, and kits thereof. The invention further provides methods of using the synthetic glycan conjugates and immunogenic compositions thereof to treat and/or reduce the risk of infectious diseases such as bacterial infections.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 29, 2018
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Chia-Hung Wang, Shiou-Ting Li
  • Patent number: 9980902
    Abstract: A method for treating intestinal fibrosis in a subject, comprising enterally administering a steroid to the subject. The steroid may be in a multiple minibead formulation.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: May 29, 2018
    Assignee: Sigmoid Pharma Limited
    Inventors: Ivan Coulter, Vincenzo Aversa
  • Patent number: 9980962
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: May 29, 2018
    Assignees: UNITY BIOTECHNOLOGY, INC, BUCK INSTITUTE FOR RESEARCH ON AGING, MAYO FOUNDATION FOR MEDICAL EDUCATIOIN AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Yi Zhu
  • Patent number: 9974878
    Abstract: The scent-dispensing animal collar accessory is adapted for use with a collar that is worn by an animal. The scent-dispensing animal collar accessory is a container that is attached to the collar. The container is used to contain a fragrance device. The fragrance device is a chemical device that releases one or more aroma compounds. Air flow through the container will disperse the one or more aroma compounds into the atmosphere in a manner that deemphasizes existing aromas that may be associated with the animal. The scent-dispensing animal collar comprises a container, an attachment device, and a fragrance device.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: May 22, 2018
    Inventor: Michael Burgess
  • Patent number: 9962363
    Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: May 8, 2018
    Assignee: Patara Pharma, LLC
    Inventors: William Gerhart, Manfred Keller, Ahmet Tutuncu, Pravin Soni
  • Patent number: 9956170
    Abstract: A method of making a dry powder pharmaceutical composition comprising: providing inactive ingredient particles; providing a micronized active ingredient; mixing the inactive ingredient particles with surface-modified nanoparticles to provide an inactive ingredient comprised of particles having surfaces with the surface-modified nanoparticles deposited on the surfaces; and/or mixing the micronized active ingredient with surface-modified nanoparticles to provide a micronized active ingredient comprised of particles having surfaces with the surface-modified nanoparticles deposited on the surfaces; and then mixing the micronized active ingredient with the inactive ingredient; the dry powder compositions made by the method; a use of said composition for the manufacture of a medicament for being delivered to the lungs of a mammal by administering a therapeutic amount of the dry powder pharmaceutical composition, and a dry powder inhalation device comprising a mouth piece, a powder containment system, and the dry po
    Type: Grant
    Filed: June 22, 2009
    Date of Patent: May 1, 2018
    Assignee: 3M Innovative Properties Company
    Inventors: Adam S. Cantor, Jacqueline M. Ganser, Michael W. Mueting, Stephen W. Stein
  • Patent number: 9918991
    Abstract: The invention includes a method of treating a mammal comprising topically applying an aqueous composition to a target site on the mammal, wherein the aqueous composition comprises: active ingredients comprising i) a cosmetic dye selected from a violet, blue or green dye, or combinations thereof, and ii) an enhancing ingredient, wherein the relative weight percentage of the cosmetic dye to the enhancing ingredient is about 1:2 to about 40:1, wherein the cosmetic dye interacts with keratinous material thereby i) substantially staining the target site and ii) inhibiting the active ingredients from significantly leaching from the target site.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: March 20, 2018
    Assignee: HYDROMER, INC.
    Inventors: Irina Grigorian, Manfred F. Dyck, Rainer Gruening
  • Patent number: 9918917
    Abstract: The invention relates to styling agents, comprising—with respect to the weight thereof—0.1 to 20 wt % of strengthening polymer(s) and 0.1 to 5 wt % of esters of the formula (I), in which R1 stands for —H or CH3, R2 stands for a straight-chain or branched alkyl group having 7 to 15 carbon atoms, and n stands for an integer from the group 1, 2, 3, 4, 5, 6, 7, 8. Said styling agents effect significantly improved curl retention, in particular significantly improved high-humidity curl retention, thus a higher degree of curl retention even in a humid environment in addition to further improved hold and improved hair feel, such as texture and combability.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: March 20, 2018
    Assignee: Henkel AG & Co. KGaA
    Inventors: Diane Metten, Julia Bibiane Lange, Bernd Richters
  • Patent number: 9918995
    Abstract: The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: March 20, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Balazs Albrecht, Michael Aven, Janine Lamar, Ingo Lang
  • Patent number: 9907784
    Abstract: There is provided the use as reducing agents of alpha-hydroxycarbonyl compounds capable of forming cyclic dimers. There is also provided corresponding methods of reducing reducible compounds, particularly reduction-activated prodrugs. Examples of the alpha-hydroxycarbonyl compounds used are dihydroxyacetone, glycolaldehyde, glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: March 6, 2018
    Assignee: MORVUS TECHNOLOGY LIMITED
    Inventor: Richard J. Knox
  • Patent number: 9889181
    Abstract: The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: February 13, 2018
    Assignee: CONTRAFECT CORPORATION
    Inventors: Raymond Schuch, Robert C. Nowinski, Michael Wittekind, Han Lee, Brent Schneider
  • Patent number: 9884036
    Abstract: The present invention provides uses of chlorogenic acid in the preparation of medicaments for treatment of psoriasis. Chlorogenic acid, a small molecular compound, is a biological response modifier focusing on the overall regulation, and has a good effect on rebuilding the homeostasis of immune function. Harmful action of chlorogenic acid on liver and kidney is not found, and it can be long-term used, without toxic and side effects on body. Chlorogenic acid is safe and effective, with low recurrence rate, and it can improve life quality of patients. It has an obvious effect on psoriasis, especially on psoriasisvulgaris and psoriasis pustulosa, thus for treatment of psoriasis, chlorogenic acid has a wide application prospects.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: February 6, 2018
    Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD
    Inventors: Jie Zhang, Lina Zhu
  • Patent number: 9867871
    Abstract: Provided herein is a composition and a method for treating nucleic acid-related eye disease.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: January 16, 2018
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventor: Sandeep Jain
  • Patent number: 9865866
    Abstract: Disclosed is a method for carbon coating on lithium titanium oxide-based anode active material nanoparticles. The method includes (a) introducing a lithium precursor solution, a titanium precursor solution and a surface modifier solution into a reactor, and reacting the solutions under supercritical fluid conditions to prepare a solution including nanoparticles of an anode active material represented by Li4Ti5O12, (b) separating the anode active material nanoparticles from the reaction solution, and (c) calcining the anode active material nanoparticles to uniformly coat the surface of the nanoparticles with carbon. Further disclosed are carbon-coated lithium titanium oxide-based anode active material nanoparticles produced by the method. In the anode active material nanoparticles, lithium ions are transferred rapidly. In addition, the uniform carbon coating ensures high electrical conductivity, allowing the anode active material nanoparticles to have excellent electrochemical properties.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: January 9, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jaehoon Kim, Jong Min Park, Kyung Yoon Chung, Agung Nugroho, Byung Won Cho
  • Patent number: 9861598
    Abstract: A ketoprofen-containing aqueous patch is provided in which not only operational efficiency in producing is improved, but also the aqueous patch has excellent storage stability and transdermal absorption of ketoprofen. The ketoprofen lysine salt-containing aqueous patch includes a backing layer and an adhesive (paste) layer laminated thereon. The aqueous patch includes as a main active ingredient a ketoprofen lysine salt completely dissolved in a paste including not glycerin but a polyethylene glycol having an average molecular weight of 1000 or less. In the ketoprofen lysine salt-containing aqueous patch, the polyethylene glycol having an average molecular weight of 1000 or less is one or more polyethylene glycols selected from the group consisting of Polyethylene glycol 200, Polyethylene glycol 400, Polyethylene glycol 600, and Polyethylene glycol 1000.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: January 9, 2018
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventor: Masahiro Inazuki
  • Patent number: 9857365
    Abstract: Described are immunoassay kits having a conjugate structure separate from an immunochromatographic strip in which the conjugate structure is freeze-dried with uniform droplet size, and related compositions and methods. The unique structure of the kits described here permits sample containing analyte to be reacted uniformly with the conjugate structure before being subjected to immunochromatography by application to the strip. This results in improved performance of the assay. In addition, the freeze-dried conjugate structure can be stored without contamination and is easy to carry. In addition, the freeze-dried conjugate structure can be rapidly and uniformly dissolved so that it is immediately allowed to react with a mixture of a buffer and a sample, the reaction product then being analyzed by immunochromatography, making it suitable for use in point-of-care testing.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: January 2, 2018
    Assignee: SD Biosensor, Inc.
    Inventors: Hyoung Gil Choi, Sung Yub Hong, Hee Young Hwang, Hyo Keun Lee
  • Patent number: 9833439
    Abstract: The present invention relates to a method for treating spinal muscular atrophy and other related neuromuscular disorders in a subject in need thereof, said method comprising administering a therapeutically effective amount of an ERK inhibitor, such as Selumetinib to said subject.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: December 5, 2017
    Assignees: UNIVERSITE PARIS DESCARTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frédéric Charbonnier, Olivier Biondi
  • Patent number: 9808423
    Abstract: The present invention provides processes for preparing suspension aerosol formulations, wherein the particles for inhalation are formed in situ during the process of manufacturing the formulation. In one aspect of the invention, a process for preparing a suspension aerosol formulation comprises the steps of: (a) dissolving one or more medicaments in one or more solvents to form a solution; and (b) mixing one or more propellants with the solution under conditions effective to precipitate, entirely or partially, at least one of the medicaments.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: November 7, 2017
    Assignee: Generics [UK] Limited
    Inventors: Li Li Bovet, Jay T. Holt
  • Patent number: 9808530
    Abstract: A composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof, in combination with an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof is provided. Further, use of an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof as an anti-foaming agent in a composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof is provided.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: November 7, 2017
    Assignee: Astellas Pharma Europe Ltd.
    Inventors: Yoshiyuki Murakami, Hikaru Saito
  • Patent number: 9801834
    Abstract: This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: October 31, 2017
    Assignee: M ET P PHARMA AG
    Inventor: Claudia Mattern
  • Patent number: 9795564
    Abstract: A waterless foamable carrier and pharmaceutical composition which is suitable for external and internal administration is disclosed. The composition is single phase and includes at least one liquid oil; and a glyceride. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: October 24, 2017
    Assignee: FOAMIX PHARMACEUTICALS LTD.
    Inventors: Dov Tamarkin, David Schuz, Yohan Hazot, Elana Gazal
  • Patent number: 9789123
    Abstract: Stable pharmaceutical compositions and processes for making same for the treatment of psoriasis. The compositions may be nanoemulsions having nano size droplets of one or more anti-psoriasis agents, e.g. clobetasol and/or salicylic acid. The compositions exhibit improved permeability and bioavailability.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: October 17, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Sunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh, Jitendra Dasharathlal Patel, Jinesh Suresh Pancholi
  • Patent number: 9777123
    Abstract: Low molecular weight sulfated beta-O4 lignin (SbO4L) are potent inhibitors of coagulation with high selectivity.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: October 3, 2017
    Assignee: Virginia Commonwealth University
    Inventors: Umesh R. Desai, Jay Thakkar, Akul Mehta
  • Patent number: 9757337
    Abstract: The present invention relates to novel multicompartmental lipid nanoparticles (or cellisomes) with excellent stability comprising a first lipophilic compartment (lipid matrix) partly anchored to a second hydrophilic compartment delimited by a phospholipid bilayer (bilayer), as well as the method for preparing same and the use thereof as a vector for administering a wide variety of molecules of interest.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: September 12, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE PARIS-SUD
    Inventors: Vincent Faivre, Sylviane Lesieur, Michel Ollivon, Modibo Ouattara, Tri Truong Cong
  • Patent number: 9750786
    Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: September 5, 2017
    Assignee: Amarillo Biosciences, Inc.
    Inventors: Martin Joseph Cummins, Chau-Ting Yeh, Ching-Yuan Lee